A post-hoc analysis of the HAWK and HARRIER trials presented at ASRS showed >=50% of patients achieved sustained retinal dryness by weeks 8 and 4 with Beovu and by weeks 12 and 8 with aflibercept, respectively1 The analysis also showed >=75% of p…
If approved, Adakveo would be the first targeted sickle cell disease therapy available for use in EuropeCHMP opinion supported by data showing Adakveo significantly reduced the rate of vaso-occlusive crises, with patients on Adakveo spending fewer days…
As we continue to expand our manufacturing capacity for transformative CAR-T cell therapy (Chimeric Antigen Receptor T-cell therapy), the European Medicines Agency (EMA) recently approved two European sites for commercial manufacturing. The sites locat…
Jakavi® demonstrated superior overall response rate in patients with chronic graft-versus-host disease (GvHD) compared to best available therapy, building on previous positive findings in acute GvHD1 Study also met key secondary endpoints, significantl…
Media ReleaseEnglish (PDF 0.2 MB) | Deutsch (PDF 0.2 MB) | Français (PDF 0.3 MB) …
Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6% (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD): Innovative Medicines grew sales 7% (cc, +5% USD) and core opera…
Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptomsPortfolio will be sold at zero-profit to governments in up …
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) was superior to once-daily IND/MF (QMF149) in improving the lung function of patients whose asthma is uncontrolled with LABA/ICS standard-of-care treatment1 In secondary analyses, improvements in lu…
European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS1* Optional digital companion with sensor and a…
Company finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related to the company’s support of certain independent char…